Solvotrin Therapeutics
PrivateLast Round
Debt
Apr 29, 2025
Est. Valuation
$53.27M
Total Funding Raised
$3.96M
Company Overview
Solvotrin Therapeutics operates in Healthcare & Life Sciences and is based in Cork. Its latest recorded funding round was a Debt round in April 2025.
Solvotrin Therapeutics is a healthcare development company that focuses on optimizing established therapies through innovative, patent-protected science, with a flagship product line of oral iron supplements marketed as Active Iron.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, D2C Brands, E-commerce
Business Model
B2C
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Solvotrin Therapeutics Comparables
Compare Solvotrin Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BetterYou | 83% | |
| Zooki | 83% | |
| Aurobindo Pharma Limited | 79% |
For institutional investors. Book with your work email.
Solvotrin Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Apr 29, 2025 | ||||
| VC Round | Nov 2, 2020 | ||||
| VC Round | Jun 8, 2018 | ||||
| Series A | Feb 10, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Solvotrin Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RAB Capital | VC Round |
| Zeus Packaging | Series A |
| Elkstone | VC Round, Series A |
| Enterprise Ireland | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 29, 2025
Completed a debt financing round.
- Nov 2, 2020
$8M round led by Elkstone and RAB Capital.
For institutional investors. Book with your work email.
Solvotrin Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Solvotrin Therapeutics's valuation, stock price, and market status.
Is Solvotrin Therapeutics a public or private company?
Solvotrin Therapeutics is a private company.
What is the current stock price of Solvotrin Therapeutics?
Solvotrin Therapeutics is a private company, so its shares have no public market price. Caplight tracks Solvotrin Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Solvotrin Therapeutics worth (valuation)?
Solvotrin Therapeutics's valuation is estimated at $53.3M based on funding round data.
Can I buy Solvotrin Therapeutics stock?
Solvotrin Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Solvotrin Therapeutics's last funding round?
Solvotrin Therapeutics's most recent funding round was Debt on April 29, 2025.
Who are the main investors in Solvotrin Therapeutics?
Key investors in Solvotrin Therapeutics include RAB Capital, Elkstone.
Will Solvotrin Therapeutics IPO soon?
No public IPO plans have been announced for Solvotrin Therapeutics.
How can I track Solvotrin Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Solvotrin Therapeutics's shares on secondary markets.